These discrepancies may be primarily due to the different model adopted: i.e. LCLs from TARDBP-mutated patients versus transgenic mouse models or fibroblasts from ALS patients (Magrané et al., 2014; Onesto et al., 2016; Xu et al., 2010). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.